Investing

First Look Analysts Research Calls for Tuesday, January 31

24/7 Wall St. Staff

Published: January 31, 2023 6:31 am

This report was sent to Briefing.com subscribers earlier today. 

Upgrades:

> FibroGen (FGEN) upgraded to Outperform from Mkt Perform at William Blair

> Inter & Co (INTR) upgraded to Buy from Neutral at Goldman; tgt lowered to $4.20

> LyondellBasell (LYB) upgraded to Overweight from Neutral at Atlantic Equities; tgt $110

> New Fortress Energy (NFE) upgraded to Buy from Neutral at BTIG Research; tgt $50

> Societe Television Francaise 1 (TVFCF) upgraded to Equal Weight from Underweight at Barclays

> WPP plc (WPP) upgraded to Overweight from Equal Weight at Barclays

Downgrades:

> Bank of America (BAC) downgraded to Neutral from Overweight at Atlantic Equities; tgt $40

> Eastern Bankshares (EBC) downgraded to Underweight from Neutral at JP Morgan; tgt lowered to $15

> Invitae (NVTA) downgraded to Sell from Neutral at Goldman; tgt $2

> iStar (STAR) downgraded to Mkt Perform from Outperform at Raymond James

> Nu Skin (NUS) downgraded to Hold from Buy at Jefferies; tgt lowered to $39

> Q2 Holdings (QTWO) downgraded to Neutral from Outperform at Robert W. Baird; tgt $32

> RELX (RELX) downgraded to Equal Weight from Overweight at Barclays

> Ubisoft (UBSFY) downgraded to Underperform from Buy at Jefferies

Others:

> Incyte (INCY) initiated with an Overweight at Piper Sandler; tgt $100

> Kura Oncology (KURA) initiated with a Buy at Stifel; tgt $25